At the forefront of therapies for rare and orphan diseasesTM
HOME CONTACT US         
Share
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events
 
Amicus Therapeutics is a biopharmaceutical company developing next-generation treatments for a broad range of human genetic diseases, with a focus on improving therapies for lysosomal storage diseases.
More...
NEWS
01/26/2015 Amicus Therapeutics Announces Presentations and Posters at Lysosomal Disease Network WORLD Symposium
01/12/2015 Amicus Therapeutics Provides Full-Year 2015 Strategic Outlook and Financial Guidance
01/08/2015 Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac Endpoints From Fabry Monotherapy Study 011 and Long Term Extension Study
More...

GENERAL NEWS
One Dad’s 14-Year Quest for Cure
By GEETA ANAND

Seven months ago, Megan Crowley made a gutsy decision: to undergo a radical surgery to  straighten out her spine, which has been crippled by Pompe disease. Photo: Lexey Swall
Click Here to Read the Article
Click Here to View the Video

Copyright © 2015 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy